

December 13, 2019



FSD Pharma to Present at Investor Summit on December 17

TORONTO--(BUSINESS WIRE)-- **FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9)** ("FSD Pharma" or the "Company") announces that Raza Bokhari, MD, Executive Co-Chairman and Chief Executive Officer, will present an overview of the Company at the Investor Summit conference at 2:35 p.m. ET on Tuesday, December 17, 2019 at the Kimpton Hotel Monaco in Philadelphia.

The Investor Summit is an exclusive, one-day, independent conference dedicated to connecting small cap and microcap companies with qualified investors. Mr. Bokhari will be available during the day on December 17 for one-on-one meetings. For more information about the conference or to schedule a one-on-one meeting, please contact shurry@lhai.com.

Mr. Bokhari's presentation will be webcast live and available for replay on the 'Events and Presentations' section of the 'Investors' page of the FSD Pharma website, www.fsdpharma.com, or via <https://www.webcaster4.com/Webcast/Page/2038/32606>.

About FSD Pharma

FSD Pharma is focused on the research and development of novel cannabinoid-based treatments for certain central nervous system disorders and autoimmune diseases of the skin, GI tract and musculoskeletal system, including chronic pain and on the development of the highest quality indoor grown, pharmaceutical-grade cannabis. The Company is licensed to cultivate cannabis in approximately 25,000 square feet of its facility in Cobourg, Ontario.

FSD's wholly-owned subsidiary, FV Pharma, is a licensed producer under Canada's Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its full Sale for Medical Purposes license on June 21, 2019. FV Pharma intends to cover all aspects of the cannabis industry, including cultivation, legal, processing, manufacturing, extracts and research and development.

Forward-Looking Statements

Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release, including statements relating to the Consolidation and the Company's intent to list on a major U.S. exchange, constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and

similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on FSD Pharma's current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and FSD Pharma is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20191213005024/en/>

Zeeshan Saeed, President and Founder, FSD Pharma Inc.

zeeshan@fsdpharma.com

(416) 854-8884

Investor Relations

IR@fsdpharma.com

www.fsdpharma.com

Or

LHA Investor Relations

Sanjay M. Hurry

shurry@lhai.com

(212) 838-3777

Source: FSD Pharma Inc.